October 4, 2016 / 12:26 PM / 10 months ago

BRIEF-Catabasis completes target enrollment for part B of the MoveDMD trial

1 Min Read

Oct 4 (Reuters) - Catabasis Pharmaceuticals Inc

* Completes target enrollment for part B Of The MoveDMD trial, a phase 2 trial of Edasalonexent (CAT-1004) for the potential treatment of duchenne muscular dystrophy

* Expects to report top-line safety and efficacy results from phase 2 trial in first half of Q1 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below